Acute Ischemic Stroke
Conditions
Keywords
DLBS1033, acute ischemic stroke, MRS, mNIHSS
Brief summary
This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients.
Detailed description
Patients included into the study will be randomized into two groups and receive either standard therapy alone (as control group) or standard therapy plus DLBS1033 at a dose of 490 mg three times daily (as DLBS1033 group). Standard therapy used in the study will consist of: aspirin 80 mg, simvastatin 20 mg, vitamin B complex, and citicholine 250 mg/2 mL twice daily. After hospital admission and diagnosis, patient will be handled according to the standard management for acute ischemic stroke applicable in the hospital. Right after the patient is confirmed eligible to the study, the treatment(s) will be switched immediately into the study's regimens. Clinical and laboratory examinations to evaluate the investigational drug's efficacy will be performed at baseline, day 4, and day 8 of treatment (end of study); while safety examinations will be performed at baseline and end of study.
Interventions
DRUGPlacebo
Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
DRUGDLBS1033
DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Sponsors
Dexa Medica Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female subjects with age of 18-75 years . * Has been diagnosed with acute ischemic stroke clinically confirmed by CT scan. * Modified National Institutes of Health Stroke Scale (mNIHSS) score \>= 5. * Patients present at hospital and receiving first dose of study medication within 72 hours after the onset of the stroke symptoms. * Able to take oral medication.
Exclusion criteria
* For females of childbearing potential: pregnancy and lactation period. * History of or current hemorrhagic stroke (within the last 3 months). * Transient ischemic stroke (TIA). * Patients with seizure at the onset of stroke. * History of serious head injury within the last 3 months. * History of major surgery within the last 3 months. * Serious cardiovascular conditions, such as myocardial infarction, CHF grade III and IV (NYHA classification), aorta dissection, and atrial fibrillation within the last 6 months. * Presence of severe renal or hepatic dysfunction * Presence of acute or chronic infections. * Thrombocytopenia (thrombocytes level \< 150.000/ul). * Patients with higher risks of bleeding. * Uncontrolled hypertension (systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110 mmHg). * Random plasma glucose \>= 200 mg/dL. * Current or regular use of oral anticoagulants, antiplatelets other than study medication, and herbal medicines. * Hypersensitive to the investigational product(s).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in mNIHSS score | 7 days after treatment initiation | Change in functional outcomes as measured by The Modified National Institute of Health Stroke Scale (mNIHSS) from its baseline value |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in fibrinogen level | 7 days after treatment initiation | Change in haemostatic parameter as measured by fibrinogen level from its baseline value |
| Improvement in d-dimer level | 7 days after treatment initiation | Change in haemostatic parameter as measured by d-dimer level from its baseline value |
| Liver function | 7 days after treatment initiation | Liver function measured will be: serum AST, ALT, G-GT, total bilirubin |
| Improvement in MRS | 7 days after treatment initiation | Change in functional outcomes as measured by Modified Rankin Scale (MRS) from its baseline value |
| Routine hematology | 7 days after treatment initiation | Routine hematology measured will be: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count |
| Hemostasis parameters | 7 days after treatment initiation | Hemostasis parameters measured will be: PT and aPTT |
| Adverse events | 7 days after treatment initiation | Adverse events, including bleeding events, will be observed and carefully evaluated during the expected average of 7 days of study treatment. |
| Renal function | 7 days after treatment initiation | Renal function measured will be serum creatinine |
Countries
Indonesia
Outcome results
None listed